一系列硫代酰胺酸锌 ( II ) 络合物 [Zn{SC( i Pr)NR} 2 ] n for R = i Pr ( n = 2) ( 2 ), t Bu ( 3 ) ( n = 1), Ph ( 4 ) ( n = 2) 和 Cy ( 5 ) ( n = 2) 以及一种硫代酰胺酸镉 ( II ) 络合物 [Cd{SC( i Pr)N t Bu} 2 ] 3 , ( 6 ) 被设计并合成为单一化合物-AACVD ZnS 和 CdS 的前体源。所有四种锌( II )化合物的固态结构都显示出扭曲的四面体或三角双锥几何形状,具有不同的二聚体缔合倾向,由{Zn-S}桥键介导。热重分析将 { t Bu} 衍生物3确定为最有前途的前体,因为它的分解起始时间较低 (118 °C) 且能够干净地转化为 ZnS。这归因于β-氢原子的更大可用性促进了热解机制。发现相应的硫代酰胺镉6结晶为三金属分子,缺乏适用于
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES
申请人:Selles Patrice
公开号:US20100184598A1
公开(公告)日:2010-07-22
The present invention relates to a method of preventing and/or controlling fungal infection in plants and/or plant propagation material comprising applying to the plant or plant propagation material a fungicidally effective amount of a compound of formula (I) or a salt of N-oxide thereof. In addition, the present invention also relates to a compound of formula (I).
Schaumann,E.; Grabley,F.-F., Liebigs Annalen der Chemie, 1979, p. 1702 - 1714
作者:Schaumann,E.、Grabley,F.-F.
DOI:——
日期:——
SCHAUMANN E.; GRABLEY F.-F., LIEBIGS ANN. CHEM., 1979, NO 11, 1702-1714
作者:SCHAUMANN E.、 GRABLEY F.-F.
DOI:——
日期:——
Urea Derivative
申请人:Yano Toshisada
公开号:US20090203712A1
公开(公告)日:2009-08-13
Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity.
A compound represented by the formula:
its pharmaceutically acceptable salt or solvate thereof,
wherein
X is hydrogen or the like,
Y is a group of the formula:
Z is —NR
7
— or the like,
R
1
is hydrogen or the like,
R
2
and R
3
are each independently hydrogen or the like,
n is 0 or 1,
p is 0 to 6.